# A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

> **NCT07124117** · PHASE1,PHASE2 · RECRUITING · sponsor: **OBI Pharma, Inc** · enrollment: 147 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** OBI-902

## Key facts

- **NCT ID:** NCT07124117
- **Lead sponsor:** OBI Pharma, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-04
- **Primary completion:** 2029-02-08
- **Final completion:** 2029-02-08
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07124117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07124117, "A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07124117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*